T1	Participants 88 137	normotensive patients with advanced malignancies.
T2	Participants 286 311	advanced cancer patients.
T3	Participants 445 490	41 normotensive advanced solid tumor patients
T4	Participants 1033 1066	findings in normotensive patients
